Table 3.
Associations (HR and 95% CI) between race/ethnicity and EOC risk in the overall study population, as well as restricting to postmenopausal women at baseline and to serous EOC.
| n | n cases | Age-adjusted | Multivariable adjusteda | Fully adjustedab | |
|---|---|---|---|---|---|
| Total EOC | |||||
| White (ref.) | 21,742 | 155 | 1.00 | 1.00 | 1.00 |
| African American | 17,870 | 93 | 0.74 (0.57, 0.96) | 0.74 (0.57, 0.97) | 0.77 (0.59, 1.01) |
| Native Hawaiian | 6,789 | 57 | 1.30 (0.96, 1.76) | 1.36 (0.99, 1.85) | 1.34 (0.98, 1.84) |
| Japanese American | 25,028 | 161 | 0.83 (0.66, 1.03) | 0.79 (0.63, 0.99) | 0.79 (0.63, 1.00) |
| Latina | 20,196 | 141 | 0.93 (0.74, 1.17) | 0.96 (0.76, 1.22) | 1.02 (0.80, 1.30) |
| Postmenopausal women | |||||
| White (ref.) | 17,590 | 132 | 1.00 | 1.00 | 1.00 |
| African American | 15,350 | 83 | 0.74 (0.57, 0.98) | 0.75 (0.57, 0.99) | 0.78 (0.58, 1.04) |
| Native Hawaiian | 4,932 | 45 | 1.31 (0.94, 1.84) | 1.37 (0.97, 1.93) | 1.36 (0.96, 1.93) |
| Japanese American | 20,471 | 138 | 0.82 (0.65, 1.04) | 0.79 (0.62, 1.00) | 0.79 (0.61, 1.01) |
| Latina | 17,425 | 122 | 0.90 (0.70, 1.15) | 0.93 (0.72, 1.20) | 1.00 (0.77, 1.30) |
| Serous EOCc | |||||
| White (ref.) | 21,742 | 122 | 1.00 | 1.00 | 1.00 |
| African American | 17,870 | 71 | 0.70 (0.52, 0.94) | 0.70 (0.52, 0.94) | 0.75 (0.55, 1.03) |
| Native Hawaiian | 6,789 | 42 | 1.25 (0.88, 1.78) | 1.27 (0.89, 1.82) | 1.30 (0.90, 1.87) |
| Japanese American | 25,028 | 113 | 0.72 (0.56, 0.93) | 0.69 (0.53, 0.89) | 0.67 (0.51, 0.87) |
| Latina | 20,196 | 99 | 0.83 (0.63, 1.08) | 0.83 (0.63, 1.10) | 0.89 (0.67, 1.18) |
Cox proportional hazards models adjusted for baseline age (continuous) and menopausal status (pre-/peri- [ref.], postmenopausal), use of OCs (never [ref.], ever), and number of children (0 [ref.], 1, 2, 3, ≥4)
Models additionally adjusted for age at menarche (<13 [ref.], 13-14, ≥15years), age at natural menopause (if postmenopausal; <44 [ref.], 45-49, 50-54, ≥55years, surgical or unknown type of menopause), duration of PMH use (if postmenopausal; never [ref.], <5, ≥5years), duration of OC use (never [ref.], <5, ≥5years), hysterectomy (no [ref.], yes), family history of breast and/or ovarian cancer (no [ref.], yes, missing), diabetes (no [ref.], yes) and smoking status (never [ref.], ever).
serous/carcinoma not otherwise specified histological subtype. Abbreviations: 95% CI: 95% confidence interval; EOC: epithelial ovarian cancer; HR: hazard ratio.